- Home
- Companies
- north america
- tumor cells
Show results for
Refine by
Industries served
- Medical / Health Care
- Chemical & Pharmaceuticals
- Agriculture
- Monitoring and Testing
- Water and Wastewater
- Energy
- Mining
- Banking & Finance / Insurance / Legal
- Waste and Recycling
- Oil, Gas & Refineries
- Environmental
- Health and Safety
- Air and Climate
- University / Academia / Research
- Government
- Manufacturing, Other
- Food and Beverage
Tumor Cells Suppliers In North America
102 companies found
based inVictoria, BRITISH COLUMBIA (CANADA)
Established in 2007, StressMarq Biosciences is a bioreagents company producing high quality, cutting edge research products for the life sciences and drug discovery/biopharma markets. StressMarq is a market leader in the development and ...
Product Name: mTOR Antibody (pSer2448). Description: Rabbit Anti-Human mTOR (pSer2448) Polyclonal. Species Reactivity: Human, Mouse, Rat. Applications: WB, IHC. Antibody Dilution: WB (1:250-1:1000); IHC (1:25-1:100); optimal dilutions for assays ...
based inHouston, TEXAS (USA)
CUSABIO is a National High-Tech Enterprise with research, production and sales in one. After 16 years of effort, CUSABIO has become a good partner to researchers through worldwide. We are dedicated to providing 60,000+ validated antibodies, 10,000+ ...
based inMalvern, PENNSYLVANIA (USA)
Since our founding in 2001, we have had one singular obsession: We strive to give our clients a personalized and collaborative research experience. We are here to help you find the answers you need to develop the best possible drug candidate for ...
In collaboration with the bioinformatics firm 4HF Biotech GmbH which is a bioinformatics firm specializing in cancer data mining to discover new anti-cancer drugs, we offer data mining for analysis of the genetic signature of tumor ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family. Dual targeting of 4-1BB and OX40 provides synergistic ...
based inChicago, ILLINOIS (USA)
In 2007, our engineers using radar technology and machine learning to help the U.S. Army catch bad guys figured out how to use that same technology to catch bad cancer cells. We have been hard at work for over 12 years experimenting, improving ...
based inWoodland Hills, CALIFORNIA (USA)
EntroGen offers end-to-end molecular diagnostic solutions by providing hardware, reagents and software. Starting from automated nucleic acid extraction and culminating in genomic interpretation with proprietary software embedded for key decision ...
The KRAS gene encodes a small GTPase that plays a key role in transducing signals from the epidermal growth factor receptor (EGFR) to downstream effectors. KRAS mutations have been commonly found in several types of human malignancies, such as ...
based inSan Diego, CALIFORNIA (USA)
At Kura Oncology, we are committed to realizing the promise of precision medicines for the treatment of cancer. The genomics revolution is transforming how we treat cancer. We now understand that a patient’s response to treatment depends in part on ...
With the advent of precision medicines that can target unique molecular or genetic features of a patient’s tumor, the field of oncology has a host of alternatives to one-size-fits-all treatments. This is a major advance over traditional ...
based inHuntsville, ALABAMA (USA)
SynVivo is a cell-based microfluidic organ-on-chip platform that provides a biologically realistic microenvironment for the real-time study of cellular behavior, drug delivery, and drug discovery. This proprietary technology links the high-tech ...
The SynVivo platform delivers a physiologically realistic model (including flow and shear) and enables real-time tracking of rolling, adhesion, and migration processes. The model recreates a histological slice of co-cultured tissue and/or ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
in a single, transferable, conditionally active design. Right Place at the Right Time. With PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting, the ProTECT platform delivers multifunctional tumor-specific activity while ...
based inSeattle, WASHINGTON (USA)
SEngine Precision Medicine empowers patients and oncologists with more informed treatment options. SEngine's high-throughput technology simultaneously tests more than 200 cancer drugs against a patient's unique tumor organoid outside the body. The ...
Guiding drug discovery with proprietary high throughput 3D patient cell technology and genomics will drastically increase the success of novel drug candidates and directly result in faster development at reduced costs. SEngine ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
ADCs are not one-size-fits-all. The Dolasynthen platform enables an iterative approach to develop the right ADC for a given indication through customization and optimization. Dolasynthen utilizes a synthetic scaffold for precise control of DAR (from ...
based inSan Diego, CALIFORNIA (USA)
BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA. Our mission is to accelerate research and discovery by providing the highest quality ...
based inMalvern, PENNSYLVANIA (USA)
We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase ...
The cornerstone of our work is the recognition that oxygen metabolic pathways play important roles in human biology and ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
Vγ9Vδ2 T cells belong to the first line of defense against cancer and have the potential to elicit deep and durable responses in the ...
based in, CALIFORNIA (USA)
At Delee we’re fundamentally changing not only the way cancer is detected but also how it could be treated. By developing a device capable of capturing Circulating Tumor Cells (CTCs) in a faster and more effective way than the current technologies ...
based inMalmö, SWEDEN
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Oncoral is a novel oral irinotecan tablet in ...
based inBlacksburg, VIRGINIA (USA)
CytoBuffer was developed to keep your cells at the forefront in electromaniuplation experiments such as electrophoresis, dielectrophoresis, droplet manipulations, and many more. Its tailored formula will return a variety of cell types & origins with ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
based inShanghai, CHINA
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...
ES104 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. VEGF also ...
based inNew York, NEW YORK (USA)
We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we seek to capitalize on ...
Our licensed gene therapy, CO-sTiRNA™, is a dual-action STAT3 inhibitor. STAT3 is a gene that drives tumor cell growth and anti-tumor immune suppression. CO-sTiRNA™ is a highly selective ...
